10 Big Names Bleed Double Digits

Ten stocks mirrored a lackluster performance in the broader market on Tuesday, posting hefty double-digit losses primarily due to disappointing earnings performance and a lower growth outlook for the rest of the year.

Meanwhile, the Nasdaq led the drop with 0.65 percent, followed by the S&P 500 at 0.49 percent, and the Dow Jones at 0.14 percent.

In this article, we name the 10 worst-performing stocks on Tuesday and detail the reasons behind their weak performance.

To compile the list, we focused on stocks with at least $2 billion in capitalization and more than 5 million shares in trading volume.

A man in long sleeves looking at stock market data. Photo by Tima Miroshnichenko on Pexels

10. Hims & Hers Health, Inc. (NYSE:HIMS)

Hims & Hers fell by 12.36 percent on Tuesday to close at $55.52 apiece as investors soured on lower-than-expected revenues in the second quarter of the year.

In its updated report, Hims & Hers Health, Inc. (NYSE:HIMS) said revenues increased by 73 percent to $544.8 million from $315.6 million in the same period last year, but missed the $552 million estimates by analysts.

Net income, on the other hand, more than tripled to $42.5 million from $13.3 million in the same period last year.

For the first six months, net income soared by 277 percent to $91.99 million from $24.42 million year-on-year, while revenues jumped by 90 percent to $1.13 billion from $593 million in the same comparable period.

For the third quarter, Hims & Hers Health, Inc. (NYSE:HIMS) is targeting to reach $570 million to $590 million in revenues, as well as $2.3 billion to $2.4 billion in the full-year period.

“It’s never been more clear that we are delivering exactly what millions of people have been waiting for: access to personalized, high-quality care that meets people where they are. From the momentum of our business to the results our customers are achieving, we are more confident than ever that our model is helping people optimize their health and realize the benefits of precision medicine,” said Hims & Hers Health, Inc. (NYSE:HIMS) co-founder and CEO Andrew Dudum.

9. IAC Inc. (NASDAQ:IAC)

IAC saw its share prices decline by 13.01 percent on Tuesday to close at $34.38 apiece as investors sold off positions following a mixed earnings performance and revenue miss in the second quarter of the year.

In an updated report, IAC Inc. (NASDAQ:IAC) said revenues in the second quarter declined by 7 percent to $586.9 million from $634.4 million in the same period last year. The figure was lower by 2.4 percent than the $601.35 million expected by analysts.

Meanwhile, the company swung to a net income attributable to shareholders of $211 million from a $142 million net loss in the same period last year.

In the first half, revenues decreased by 7.9 percent to $1.16 billion from $1.26 billion in the same comparable period, while net loss attributable to shareholders narrowed by 94 percent to $5.35 million from $97.2 million.

For full-year 2025, IAC Inc. (NASDAQ:IAC) targets to hit adjusted EBITDA of $247 million to $285 million, and total operating income of $82 million to $140 million.